ORPHELIA Pharma to support the European paediatric Soft Tissue Sarcoma Study Group winter meeting
Medicines for Europe: 5th Value Added Medicines Conference, 7th November 2023, Brussels
The Medicines for Europe association represent the pharmaceutical companies supplying the largest share of medicines across Europe, it holds its 5th conference on value-added medicines on November 7th, 2023, in Brussels.
Laurent Martin, Orphelia Pharma’s Chief Pharmaceutical Affairs Officer, will attend this conference with the story and market access of Kigabeq, the first pediatric formulation of vigabatrin for the treatment of a rare form of encephalopathic epilepsy: West syndrome.
Event : BioEurope Fall 2023 – November 6-8, 2023; Munich, Germany
Gilles ALBERICI, CEO at ORPHELIA Pharma and Hugues BIENAYME, General Manager will attend the BioEurope Fall meeting to be held November 6-8, 2023 in Munich, Germany. BioEurope convenes over 5,500 attendees, representing 60 countries and 2,220+ companies, making the event the industry’s largest gathering of biopharma professionals in Europe.
Five new projects supported by our Foundation
In June 2023, our corporate Foundation and its Endowment Fund supported Clubhouse Lyon, Cheer Up !, Dans les pas du hérisson, Night Light and Les enfants de la balle
Orphelia Pharma files EU marketing authorization application for KIZFIZO®
First drinkable formulation of temozolomide for treatment of relapsed or refractory neuroblastom
ORPHELIA to present results of TEMOkids (KIZFIZO®) at the 2023 SIOP meeting
Dr. Lucy METAYER, co-investigator and pediatric oncologist at the Gustave Roussy will present the results from the pediatric TEMOkids trial on October 14, 2023 during the oral session entitled “novel therapeutic approaches” at the 55th SIOP annual congress to be held in Ottawa, Canada.
SIOPEN annual general meeting, October 4-6 2023, Ljubljana, Slovenia
Jeremy Bastid, Chief Development Officer at ORPHELIA Pharma will attend the SIOPEN annual general meeting.
The SIOPEN annual meeting brings together about 200 clinicians, investigators, researchers and patient advocates from 34 European countries to discuss on-going clinical trials, results, and work in progress in the field of neuroblastoma.
Newsletter July 2023
The following pages will tell you all about the latest projects supported by the Foundation
Four new projects supported by our Foundation
In June 2023, our corporate Foundation and its Endowment Fund supported Audition Solidarité, Génération avant-garde, Fratries and Afuté